Avatrombopag release date

Avatrombopag was approved by the U.S. Food and Drug Administration (FDA) in May 2018 for the treatment of thrombocytopenia (low platelets) in adults with chronic liver disease who are scheduled to undergo surgery. It is administered orally as atrombopag maleate salt and is marketed under the trade name Doptelet.

The study found that avatropopag reduced the need for platelet transfusions or other rescue treatments to prevent excessive bleeding before and for 7 days after invasive surgery. Platelet counts increased in patients receiving avatrombopag. Any adverse reactions during avatrombopag treatment are believed to be caused by the patient's medical condition and the nature of the invasive procedure using this drug. The European Medicines Agency decided that the benefits of avatrombopag outweighed the risks, and it was approved in the EU in June 2019 and in Australia in January 2023. Avatrombopag The original drug was approved by the State Food and Drug Administration in April 2020, with the trade name Su Kexin.

The domestically marketed original drug Avatrombopag has entered the scope of Class B medical insurance, but only eligible patients can be reimbursed. The price of a common specification of 20mg*15 tablets may be more than RMB 7,000 per box, while the original drug Avatrombopag marketed overseas is even more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates).